Stephen Liu, Chief of Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“First ESMO26 highlights episode of the IASLC podcast Lung Cancer Considered features Jacob Sands, Jarushka Naidoo and Ferdinandos Skoulidis touching on DeLLphi-305, Krascendo 1, and MOIO among others. Very impactful ESMO meeting for lung cancer!”
Listen to the podcast.
About Lung Cancer Considered
Lung Cancer Considered is the official podcast of the International Association for the Study of Lung Cancer (IASLC). It brings together experts, researchers, doctors, patients, and advocates from around the world to discuss the latest developments and challenges in lung cancer research and care.
The episode features leading experts in thoracic oncology discussing some of the key research presented at the 2026 European Society for Medical Oncology (ESMO) Congress, particularly studies that could influence the way lung cancer is treated.
The conversation covers several important trials and topics:
- DeLLphi-305 trial: New findings on tarlatamab for patients with extensive-stage small cell lung cancer (SCLC).
- KRAScendo-1 trial: Results exploring divarasib in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).
- Immunotherapy strategies: Discussion of the latest findings from the MOIO and OptiTROP-Lung06 studies.
- Immune-related toxicities: Research into ways of predicting and managing side effects caused by immunotherapy.
- Clinical practice: What these findings could mean for treatment decisions and the future care of people with lung cancer.
You may also be interested in:
- What Changes in Lung Oncology After ESMO 2026? Survival Breakthroughs, ADC Competition, and a New Era of Precision Treatment
- Krascendo 1 Phase III: Divarasib Significantly Improves Overall Survival and Progression-Free Survival Versus Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC
- DeLLphi-305: Tarlatamab–Durvalumab Redefines First-Line Maintenance in Extensive-Stage SCLC